Vitamin D Status and Severe COVID-19 Disease Outcomes in Hospitalized Patients
et al., Journal of Primary Care & Community Health, doi:10.1177/21501327211041206
, Vitamin D Status and Severe COVID-19 Disease Outcomes in Hospitalized Patients, Journal of Primary Care & Community Health, doi:10.1177/21501327211041206
Retrospective 92 hospitalized patients not showing significant differences in outcomes based on vitamin D status or supplementation.
|
risk of death, 70.0% higher, OR 1.70, p = 0.52, treatment 29, control 63, supplementation, unadjusted, RR approximated with OR, excluded in exclusion analyses:
unadjusted results with no group details.
|
|
risk of mechanical ventilation, 10.0% higher, OR 1.10, p = 0.89, treatment 29, control 63, supplementation, unadjusted, RR approximated with OR, excluded in exclusion analyses:
unadjusted results with no group details.
|
|
risk of ICU admission, 30.0% higher, OR 1.30, p = 0.61, treatment 29, control 63, supplementation, unadjusted, RR approximated with OR, excluded in exclusion analyses:
unadjusted results with no group details.
|
|
risk of death, 35.9% lower, RR 0.64, p = 0.74, high D levels (≥20ng/mL) 6 of 77 (7.8%), low D levels (<20ng/mL) 1 of 15 (6.7%), inverted to make RR<1 favor high D levels (≥20ng/mL), cutoff ≥20ng/mL, odds ratio converted to relative risk, multivariable logistic regression, outcome based on serum levels.
|
|
risk of mechanical ventilation, 56.9% lower, RR 0.43, p = 0.22, high D levels (≥20ng/mL) 8 of 15 (53.3%), low D levels (<20ng/mL) 4 of 15 (26.7%), inverted to make RR<1 favor high D levels (≥20ng/mL), cutoff ≥20ng/mL, odds ratio converted to relative risk, multivariable logistic regression, outcome based on serum levels.
|
|
risk of ICU admission, 13.1% higher, RR 1.13, p = 0.57, high D levels (≥20ng/mL) 54 of 77 (70.1%), low D levels (<20ng/mL) 9 of 15 (60.0%), inverted to make RR<1 favor high D levels (≥20ng/mL), cutoff ≥20ng/mL, odds ratio converted to relative risk, multivariable logistic regression, outcome based on serum levels.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Pecina et al., 27 Aug 2021, retrospective, USA, peer-reviewed, 4 authors, dosage not specified.
Abstract: 1041206
research-article2021
JPCXXX10.1177/21501327211041206Journal of Primary Care & Community HealthPecina et al
Original Research
Journal of Primary Care & Community Health
Volume 12: 1–7
© The Author(s) 2021
Article reuse guidelines:
sagepub.com/journals-permissions
https://doi.org/10.1177/21501327211041206
DOI: 10.1177/21501327211041206
journals.sagepub.com/home/jpc
Vitamin D Status and Severe
COVID-19 Disease Outcomes
in Hospitalized Patients
Jennifer L. Pecina1 , Stephen P. Merry1 , John G. Park1,
and Tom D. Thacher1
Abstract
Background: Vitamin D deficiency may increase the risk of severe COVID-19 disease. Objectives: To determine if
25-hydroxyvitamin D [25(OH)D] levels in patients hospitalized for COVID-19 were associated with the clinical outcomes
of days on oxygen, duration of hospitalization, ICU admission, need for assisted ventilation, or mortality. Methods: We
conducted a retrospective study of 92 patients admitted to the hospital with SARS-CoV-2 infection between April 16,
2020 and October 17, 2020. Multivariable regression was performed to assess the independent relationship of 25(OH)D
values on outcomes, adjusting for significant covariates and the hospitalization day the level was tested. Results: About 15
patients (16.3%) had 25(OH)D levels <20 ng/mL. Only 1 patient (3.4%) who had documented vitamin D supplementation
prior to admission had 25(OH)D <20 ng/mL. Serum 25(OH)D concentrations were not significantly associated with any
of our primary outcomes of days on oxygen, duration of hospitalization, intensive care unit (ICU) admission, need for
mechanical ventilation, or mortality in any of the adjusted multivariable models. Adjusting for the hospital day of 25(OH)
D sampling did not alter the relationship of 25(OH)D with any outcomes. Conclusion: Vitamin D status was not related
to any of the primary outcomes reflecting severity of COVID-19 in hospitalized patients. However, our sample size may
have lacked sufficient power to demonstrate a small effect of vitamin D status on these outcomes.
Keywords
25-hydroxyvitamin D, severe acute respiratory syndrome coronavirus 2, COVID-19, critical care
Dates received: 1 June 2021; revised: 2 August 2021; accepted: 4 August 2021.
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.